Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis.
Cancers (Basel)
; 11(12)2019 Nov 21.
Article
en En
| MEDLINE
| ID: mdl-31766332
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Cancers (Basel)
Año:
2019
Tipo del documento:
Article